|
HDL mediated efflux of cholesterol from the arterial wall: Can HDL promote removal of cholesterol from atherosclerotic lesions?
|
|
|
Current Model of HDL-C Metabolism: Reverse Cholesterol Transport
|
|
|
An appropriate model of cholesterol efflux from the atherosclerotic plaque should reflect the complex structure of the lesion itself.
|
|
|
What is the predominant form of cholesterol present in the vulnerable atherosclerotic plaque ?
|
|
|
Lipid accounts for 40% of surface area of vulnerable plaques
|
|
|
In what physical forms is cholesterol present within vulnerable plaques ?
|
|
|
Cholesterol is differentially distributed between plaque components
|
|
|
FC -rich microdomains are present in regions of human aortic tissue with lipid-containing foam cells
|
|
|
Slide 9
|
|
|
Incubation of human monocyte-derived macrophage cultures with AcLDL generates extracellular unesterified cholesterol-rich microdomains
|
|
|
Unesterified cholesterol-rich microdomains can be removed by cholesterol acceptors
|
|
|
Cholesterol is differentially distributed between plaque components
|
|
|
Zhao et al, Curr Opin Lipidol 2010
|
|
|
HDL-Mediated Cholesterol Efflux From Cholesterol-Rich Macrophages
|
|
|
Stimulation of cellular cholesterol efflux by LDR agonists in human macrophages
|
|
|
ABCG1 is highly expressed in human foam cells upon stimulation by LXR agonists
|
|
|
Cellular cholesterol efflux to HDL in human macrophages is ABCG1 independent
|
|
|
Stimulation of cholesterol efflux to HDL by LXR agonists requires the ABCA1 transporter in human macrophages
|
|
|
Cellular cholesterol efflux to HDL in human macrophages requires the CLA-1 receptor
|
|
|
In human macrophages
|
|
|
HDL: New Dimensions
|
|
|
Mechanisms of Cellular Cholesterol Efflux to HDL particles
|
|
|
Proteolytic inactivation of pre-HDL impairs ABCA1-dependent initiation of reverse cholesterol transport in the atherosclerotic plaque
|
|
|
Summary
|
|
|
What is the evidence that HDL/apoAI mediate cholesterol efflux from the plaque?
|
|
|
Long history of HDL infusion reducing atheroma burden
|
|
|
HDL Infusions
|
|
|
Impact of HDL on Plaque Evolution: Experimental Evidence for Plaque Regression
|
|
|
Reconstituted HDL (CSL111) reduced atheroma in man
|
|
|
Impact of Reconstituted HDL infusion on Peripheral Arterial disease
|
|
|
Accumulation of lipids and macrophage size in the lesions.
|
|
|
Impact of rHDL infusion on atherosclerotic lesions in the SFA
|
|
|
Can the cholesterol cargo in HDLpotentially contribute to plaque cholesterol accumulation and thence progression ?
|
|
|
apoE-HDL and Reverse Cholesterol Transport
|
|
|
ApoE- HDL
|
|
|
Are these observations relevant to emerging therapeutic approaches to raise HDL-C and normalise its function in dyslipidemic, high risk metabolic states ?
|
|
|
HDL metabolism: Impact of CETP inhibition
|
|
Share this page with your colleagues and friends: